Vexel-30/Vexel-100/Vexel-300

Paclitaxel

1st-line chemotherapy of advanced ovarian cancer or a residual disease >1 cm after initial laparotomy, in combination w/ cisplatin. 2nd-line chemotherapy of metastatic ovarian cancer after failure of standard platinum-containing therapy. Treatment of node +ve breast carcinoma following anthracycline & cyclophosphamide (AC) therapy. Initial treatment of locally advanced or metastatic breast cancer either in combination w/ anthracycline, or w/ trastuzumab in patients overexpressing HER-2 at 3+ level & for whom anthracycline therapy is not suitable. As single agent for the treatment of metastatic breast cancer in patients who failed to respond to standard treatment w/ anthracycline or in whom anthracycline therapy is not suitable. Treatment of non-small cell lung carcinoma (NSCLC) who are not candidates for potentially curative surgical intervention &/or radiation therapy. Treatment of AIDS-related Kaposi's sarcoma (KS).

1st-line treatment of ovarian cancer 175 mg/m² as IV infusion for 3 hr followed by 75 mg/m² cisplatin & therapy is repeated at 3-wk intervals, or 135 mg/m² as IV infusion over a 24-hr period followed by 75 mg/m² cisplatin & therapy is repeated at 3-wk intervals. 2nd-line treatment of ovarian cancer 175 mg/m² over 3 hr infusion w/ a 3-wk interval between courses. Adjuvant chemotherapy in breast carcinoma 175 mg/m² over 3 hr infusion every 3 wk for 4 courses following AC therapy. 1st-line chemotherapy of breast carcinoma 220 mg/m² IV over 3 hr w/ a 3-wk interval between courses in combination w/ doxorubicin 50 mg/m²; administer paclitaxel 24 hr after doxorubicin. In combination w/ trastuzumab, paclitaxel 175 mg/m² IV over 3 hr w/ a 3-wk interval between courses. 2nd-line chemotherapy of breast carcinoma 175 mg/m² over 3 hr infusion w/ a 3-wk interval between courses. Advanced NSCLC 175 mg/m² over 3 hr infusion followed by 80 mg/m² of cisplatin w/ a 3-wk interval between courses. AIDS-related KS 100 mg/m² over 3 hr IV infusion every 2 wk.

Hypersensitivity.

Avoid contact of paclitaxel w/ skin & mucous membranes. Do not re-administer until the neutrophil count is ≥1.5 x 10⁹/L (≥1 x 10⁹/L for KS patients) & the platelet count is ≥100 x 10⁹/L (≥75 x 10⁹/L for KS patients). Patients w/ severe neutropenia (neutrophil count <0.5 x 10⁹/L for a min of 7 days) or severe peripheral neuropathy. Hepatic impairment.

Cytotoxic Chemotherapy

L01CD01 - paclitaxel ; Belongs to the class of taxanes from plant alkaloids and other natural products. Used in the treatment of cancer.

Rx